← Stock Trading Canary · All insider profiles
INSIDER PROFILE · UK
Carolyn Rand
Non-Executive Chair | Non-Executive Director
Profile key: uk|carolyn rand
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 3
- Purchases · 24M
- 6
- Average purchase
- £3,281
- Gross purchase value
- £19,688
- Last purchase
- 2026-08-05
- Completed 20D events
- 5.0
- Outcome status
- PASS
Latest company: PCI PAL PLC
Companies: Cambridge Nutritional Sciences plc | PCI PAL PLC
Post-purchase outcomes
Benchmark-relative outcomes are available against FTSE 100.
- Excess return = stock return − FTSE 100 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 5Developing | 100.0% (5/5) | 40.0% (2/5) | -1.9% | -0.4% | -8.5% |
| 20D | 5Developing | 100.0% (5/5) | 20.0% (1/5) | -9.4% | -5.5% | -16.1% |
| 60D | 4Small sample | 100.0% (4/4) | 0.0% (0/4) | -20.2% | -18.9% | -26.9% |
| 120D | 4Small sample | 100.0% (4/4) | 25.0% (1/4) | -11.8% | -10.7% | -23.2% |
Research patterns
- First purchase in 12M
- 1/3
- Large purchase ≥ €100k
- 0/5
- Cluster buying · 15D
- 3/5
- Buying the dip · ≥20% below prior 52W high
- 4/5
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.